Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

What this study is about

This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.

Who can join (things the study team will check)

✅ You may be able to join if…

• Male or female ≥40 years of age
• Informed consent
• Two or more of the following risk factors for heart failure:
  • Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis of an epicardial coronary artery [50% left main stem or >70% left anterior descending, circumflex or right coronary artery])
  • An established diagnosis of diabetes (type 1 or type 2)
  • Persistent or permanent atrial fibrillation (not paroxysmal atrial fibrillation)
  • Previous ischemic or embolic stroke
  • Peripheral arterial disease (previous surgical or percutaneous revascularisation or a documented stenosis greater than 50% of a major peripheral arterial vessel).
  • Chronic kidney disease (defined as an estimated glomerular filtration rate <60mL/min/1.73m2 or eGFR 60-90mL/min/1.73m2 and UACR >300mg/g).
  • Regular loop diuretic use (any dose at any dosing interval) for >30 days.
  • COPD (evidenced by one of the following: PFTs showing airway obstruction, diagnosis by respiratory physician, CT scan reporting presence of emphysema or treatment with national guideline advocated COPD therapy).

🚫 You may not be able to join if…

• Inability to give informed consent e.g., due to significant cognitive impairment
• Previous documented diagnosis of heart failure
• Current renal replacement therapy
• Anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period

Where this trial is running

• Cleveland Clinic, Cleveland, Ohio, United States
• University of British Columbia, Vancouver, British Columbia, Canada
• University of Montreal, Montreal, Quebec, Canada
• Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
• Karolinska University Hospital, Stockholm, Sweden
• Uppsala University, Uppsala, Sweden
• University of Glasgow, Glasgow, Scotland, United Kingdom

Who to contact

Mark C Petrie, MbChB · +44(0) 141 330 2677 · mark.petrie@glasgow.ac.uk

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05919342.